Regeneron: The 20-Year Overnight Success

Discover how a 'near-death' biotech startup pivoted from failed nerve drugs to a scientific powerhouse fueled by genetically engineered mice.[INTRO]ALEX: Imagine you spent twenty years and hundreds of millions of dollars failing at your job, only to end up creating a drug cocktail that saved a sitting U.S. President during a global pandemic. JORDAN: Wait, twenty years of losing money? How does a company even survive until lunch, let alone two decades, without a product?ALEX: That is the wild story of Regeneron—the biotech giant that proves if you own the world’s most sophisticated mice, you can eventually own the medicine cabinet.JORDAN: Okay, you’ve piqued my interest. Let’s talk about these super-mice and how they built a multibillion-dollar empire out of two decades of failure.[CHAPTER 1 - Origin]ALEX: It all starts in 1988 with a neurologist named Leonard Schleifer and a brilliant young scientist named George Yancopoulos. Their goal was incredibly ambitious: they wanted to use nerve growth factors to cure ALS and other neurological diseases.JORDAN: So they were going for the hardest targets right out of the gate. Did they have the cash to back it up?ALEX: Leonard was a master fundraiser. He put in his own million, got another million from family, and then landed a massive thirty-five-million-dollar venture round from Procter & Gamble. JORDAN: That’s a lot of pressure. I’m guessing the ALS cure didn’t happen by 1990?ALEX: Not even close. The 1990s were what the founders literally called a "near-death experience." Their clinical trials for nerve diseases kept failing, one after another, and the stock price was in the basement.JORDAN: So why didn't they just fold? Most companies would have been stripped for parts by year five.ALEX: They had a secret weapon: Roy Vagelos, the legendary former CEO of Merck, joined their board. He helped them realize that instead of betting everything on one specific drug, they needed to build a technology engine—a way to manufacture human antibodies at scale.[CHAPTER 2 - Core Story]JORDAN: Okay, so the pivot happens. If they aren't curing ALS, what are they building in the lab?ALEX: They spent the early 2000s building what they called the "Veloci-Suite." The crown jewel was VelocImmune—a project where they genetically engineered mice to produce fully human antibodies.JORDAN: Human antibodies? From a mouse? That sounds like science fiction.ALEX: It’s essentially a shortcut to evolution. Usually, if you put a human protein in a mouse, the mouse’s immune system rejects it. Regeneron figured out how to swap the mouse’s immune genes for human ones, so the mouse becomes a living factory for human medicine.JORDAN: That sounds expensive. Did it actually pay off, or was it just more cool science that didn't make money?ALEX: It paid off in a massive way in 2011. They launched a drug called Eylea for wet age-related macular degeneration—basically a condition that causes blindness. JORDAN: I remember seeing the ads for that. It was a massive hit, right?ALEX: It was a monster. Eylea turned blindness from an inevitability into a manageable condition and started generating billions in revenue. Suddenly, the company that couldn't catch a break for twenty years had more cash than they knew what to do with.JORDAN: And they didn’t stop there. I keep hearing their name in relation to the pandemic.ALEX: Exactly. When COVID-19 hit, they used that same mouse technology to identify the most potent antibodies against the virus. They developed REGEN-COV in record time, and by October 2020, it was being flown to Walter Reed to treat President Donald Trump.JORDAN: It’s crazy how a company that almost went bankrupt trying to fix nerves ended up being the go-to for a respiratory pandemic.[CHAPTER 3 - Why It Matters]ALEX: Today, Regeneron is a titan. Their drug Dupixent is a multi-billion dollar treatment for everything from asthma to severe eczema. But their impact is also about how we find new drugs.JORDAN: Right, they aren't just guessing anymore; they have this massive Genetics Center sequencing millions of people, don't they?ALEX: They do. They’ve sequenced over 1.5 million people to find genetic mutations that naturally protect against disease. They are essentially using human data to tell them what the next drug should be.JORDAN: But there's a catch, isn't there? These drugs aren't cheap.ALEX: That’s the big controversy. Regeneron is often at the center of the drug-pricing debate. Some of their treatments cost thirty to forty thousand dollars a year, which leads to massive profits and record-breaking paydays for the founders.JORDAN: So it’s the classic pharma dilemna: incredible, life-saving innovation on one side, and a price tag that breaks the bank on the other.ALEX: It is. In 2021 alone, Leonard Schleifer’s compensation package was over four hundred and fifty million dollars. People are left asking: is the science worth that much to society?[OUTRO]JORDAN: It's a complicated legacy for sure. If I have to remember one thing about Regeneron, what is it?ALEX: Remember that they proved that investing in foundational technology platforms—rather than just chasing single miracle cures—is what truly transforms modern medicine.JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai